Consumer Cyclical
Live Price
Offline$0.997
-1.29% today
1Y Change
-14.07%
Window
Jun 27, 2025 → Jun 18, 2026
Coverage: 245 bars · Jun 27, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
MEDIROM Healthcare Technologies Inc. (MRM) is a Consumer Cyclical stock with a market cap of $980.00M and listed on NASDAQ. The stock last traded around $1.00 and down 14.1% across the available one-year price window (Jun 27, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -92.4%, EPS growth of -74.5%, a dividend yield of 0.0%. What stands out right now is revenue -92.4%, EPS -74.5%, free cash flow 0.0% with operating margin 10.3% and ROIC 1.7%. Valuation is more restrained than many high-expectation growth names at P/E 25.8 and price/sales 1.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MRM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Cyclical peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MRM
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MRM Max Drawdown
-69.05%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for MRM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.3B
-38.2% YoY
FY Net Income
-$539.2M
+45.6% YoY
Free Cash Flow
-$440.0M
+32.6% YoY
Revenue Growth
-92.4%
EPS Growth
-74.5%
Gross Margin
96.6%
Net Margin
9.3%
Income statement
JPY
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 8.3B | 6.8B | 7.0B | 5.4B | 3.3B |
| Gross Profit | 2.2B | 1.6B | 1.9B | 1.4B | 429M |
| Operating Income | -18M | -392M | 97M | -471M | -746M |
| EBITDA | 387M | 310M | 374M | -276M | -551M |
| Net Income | 149M | 115M | 149M | -991M | -539M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 329M | 106M | 605M | 371M | 1.4B |
| Total Assets | 8.1B | 6.8B | 6.7B | 5.8B | 5.7B |
| Total Liabilities | 6.9B | 6.6B | 6.8B | 6.0B | 5.2B |
| Shareholder Equity | 933M | 211M | -59M | -208M | 491M |
| Total Debt | 4.0B | 3.6B | 3.2B | 2.8B | 2.6B |
| Net Debt | 3.6B | 3.5B | 2.6B | 2.4B | 1.1B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
366M
+34.2% YoY
Capital Expenditures
74M
+23.1% YoY
Free Cash Flow
440M
+32.6% YoY
Key ratios
Gross Margin
96.6%
Operating Margin
10.3%
Net Margin
9.3%
ROE
8.8%
Debt / Equity
1.75x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.